J&J gains EU clearance for $21 bln Synthes deal
BRUSSELS, April 19
BRUSSELS, April 19 (Reuters) - U.S. healthcare company Johnson & Johnson secured EU clearance on Thursday to purchase Swiss medical device maker Synthes Inc. for about $21 billion, a move to boost its orthopaedics franchise.
The deal is J&J's largest acquisition. It won EU regulatory approval after J&J committed to divest its trauma business in the EU, which had raised competition concerns.
The European Commission, the EU's competition watchdog, said in a statement that the merged group would continue to face competition from several strong rivals and that customers would still have sufficient alternative suppliers.
"We obtained remedies to ensure that competition will remain strong in these markets, for the ultimate benefit of patients and social security systems," EU Competition Commissioner Joaquin Almunia said in a statement.
- Malaysian plane presumed crashed; questions over false IDs |
- CORRECTED-UPDATE 4-Malaysia Airlines plane crashes in South China Sea with 239 people aboard - report
- China draws 'red line' on North Korea, says won't allow war on peninsula
- Warning shots fired to turn monitors back from Crimea |
- Malaysian plane crashed off Vietnam coast: state media